PostEra , a biotechnology company specializing in artificial intelligence for preclinical drug discovery, announced a multi-target collaboration with Amgen, a leading biotechnology company.
The collaboration will leverage PostEra’s AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen’s drug discovery expertise, to advance up to five small molecule programs. Once a certain number of programs enter the collaboration, Amgen will have the option to access some of PostEra’s key AI technologies for its internal programs, outside of the collaboration.
The agreement includes upfront funding and milestone payments, as well as royalties on any approved products arising from the collaboration.
“We are excited to collaborate with Amgen, which has deep expertise across multiple therapeutic areas and an illustrious history of tackling some of the most difficult targets in biology,” said Dr. Alpha Lee, CSO of PostEra. “The Proton platform has been repeatedly validated in its ability to meaningfully address even the most challenging small molecule drug discovery programs.” “We believe that AI can significantly improve drug discovery, but we are also aware of the hype around this technology. As such, we have worked hard to demonstrate Proton’s value in real-world discovery programs, with multiple partners, in several therapeutic areas,” added Aaron Morris , CEO of PostEra.
PostEra was founded in 2019 and its machine learning technology is based on pioneering academic research conducted by its founding scientists. PostEra’s technology addresses some of the key challenges in small molecule drug discovery by industrializing the design, manufacturing and testing cycle of medicinal chemistry. PostEra is advancing small molecule programs through partnerships with biopharmaceuticals while also advancing its own internal portfolio. The company has closed $1 billion in AI partnerships between multiple biopharmaceutical partners.
SOURCE: PRNewswire